Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia
WEE1 is a cell cycle and DNA damage response kinase that is emerging as a therapeutic target for cancer. AZD1775 is a small molecule inhibitor of WEE1, currently in early phase clinical trials as a single agent and in combination with more conventional anti-neoplastic agents. As resistance to kinase...
Na minha lista:
| Principais autores: | , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2020-03-01
|
| Serier: | Frontiers in Oncology |
| Fag: | |
| Online adgang: | https://www.frontiersin.org/article/10.3389/fonc.2020.00296/full |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|